2023 World Conference on Lung Cancer (Posters)-EP11.03. The Economic Burden of Lung Cancer (NSCLC) In the County of Gävleborg - Sweden

Pdf Summary

This study analyzed the economic burden of non-small cell lung cancer (NSCLC) in the county of Gävleborg, Sweden. The researchers aimed to provide real-world data on the actual care costs of NSCLC, which can be used to inform health-economic models and decision-making processes. <br /><br />The study utilized a random sample of patients newly diagnosed with NSCLC in 2020 from the Regional Cancer Registry. Data was retrospectively collected from patient charts, including patient and tumor characteristics, treatment details, adverse events, survival, and resource utilization. Health utilization data, such as hospital and outpatient costs, were also collected. The analysis was conducted from the economic perspective of the healthcare institution. <br /><br />The results showed that a total of over 13,000 health service events were captured, with laboratory tests, diagnostic imaging, and ambulatory visits comprising 80% of the service events. Patient admissions and therapy accounted for 75% of the costs. The majority of the overall costs occurred within three months of diagnosis. The cost for imaging was 412,854 USD, diagnostic procedures costed 245,126 USD, chemotherapy costed 250,254 USD, and immunotherapy costed 358,720 USD. <br /><br />The study concluded that the real-world data on NSCLC costs provided valuable information for health-economic models and decision-making by hospital, industry, and governmental stakeholders. The findings highlighted that the majority of costs occurred soon after diagnosis, indicating the need for early and effective interventions. The strength of the study lies in its detailed and accurate assessment of costs for policy-making purposes. <br /><br />In summary, this study presented the economic burden of NSCLC in Gävleborg, Sweden, and highlighted the importance of real-world data in health-economic analysis and decision making. The findings shed light on the costs associated with NSCLC treatment and provided insights for healthcare stakeholders to optimize resource allocation and interventions.

Asset Subtitle

Hirsh Koyi

Meta Tag

Speaker Hirsh Koyi

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

non-small cell lung cancer

NSCLC

economic burden

Gävleborg

real-world data

health-economic models

decision-making processes

hospital costs

resource utilization

early interventions